Avid, PETNET align to assess brain imaging agent for Alzheimer's
Avid Radiopharmaceuticals and PETNET Solutions, a subsidiary of Siemens Healthcare, have shipped the first dose of Avid’s molecular imaging agent for PET imaging of B-amyloid deposits in the brain, Florbetapir.
The Philadelphia based Avid said its Florbetapir (18F-AV-45) is currently being evaluated in Phase III clinical studies in the U.S. for brain PET imaging of B-amyloid in patients with suspected Alzheimer’s disease or mild cognitive impairment.
PETNET manufactures Florbetapir at multiple facilities in the U.S. and is expanding the production to support the clinical development of Florbetapir.
The Philadelphia based Avid said its Florbetapir (18F-AV-45) is currently being evaluated in Phase III clinical studies in the U.S. for brain PET imaging of B-amyloid in patients with suspected Alzheimer’s disease or mild cognitive impairment.
PETNET manufactures Florbetapir at multiple facilities in the U.S. and is expanding the production to support the clinical development of Florbetapir.